Journey Medical
DERM
35 hedge funds and large institutions have $13.3M invested in Journey Medical in 2024 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 11 closing their positions.
99% more capital invested
Capital invested by funds: $6.68M → $13.3M (+$6.63M)
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
6% more funds holding
Funds holding: 33 → 35 (+2)
2.33% more ownership
Funds ownership: 14.52% → 16.85% (+2.3%)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$1.21M |
| 2 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$470K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$422K |
| 4 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$260K |
| 5 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
+$252K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$528K |
| 2 |
Walleye Capital
New York
|
-$291K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$134K |
| 4 |
Millennium Management
New York
|
-$133K |
| 5 |
HBCM
Heron Bay Capital Management
Bloomfield Hills,
Michigan
|
-$124K |
DERM Hedge Fund Activity: Q2 2024 in Review
35 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Journey Medical (DERM) for Q2 2024, worth a combined $13.3M — up 99% from $6.68M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new DERM positions and 11 closed out — a net gain of 2 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $1.21M. The largest seller was Acadian Asset Management, cutting an estimated $528K.
- 35 institutional investors held Journey Medical (DERM) as of Q2 2024, up from 33 in Q1 2024.
- Funds reported $13.3M of Journey Medical stock for Q2 2024, up 99% quarter-over-quarter.
- 13 funds opened new Journey Medical positions in Q2 2024 and 11 closed out, a net change of +2 holders.
- The largest Journey Medical buyer in Q2 2024 was Cambridge Investment Research Advisors, an estimated $1.21M added.
- The largest Journey Medical seller in Q2 2024 was Acadian Asset Management, an estimated $528K sold.
Based on aggregated 13F filings for Q2 2024.